ArchiMed
ArchiMed is a healthcare-focused private equity firm investing globally in small, mid-sized, and selected larger healthcare businesses.
- Healthcare and life sciences private equity investment firm
- Healthcare & Life Sciences PEF
- Tier II
Overview
ArchiMed is a healthcare-focused private equity firm investing globally in small, mid-sized, and selected larger healthcare businesses. Its activity spans life sciences tools, diagnostics, medtech, pharmaceutical services, healthcare services, and other regulated subsectors.
The firm applies a dedicated healthcare model supported by sector specialists and operating resources. This structure is valuable in businesses where product quality, scientific knowledge, regulatory execution, international commercialization, and operational scaling must be managed together. Within The Economy Wiki, the firm is connected to the Healthcare & Life Sciences PEF market category.
Firm facts
| Institution | ArchiMed |
| Type | Healthcare and life sciences private equity investment firm |
| Headquarters | Lyon, France |
| Founded | 2014 |
| Primary ranking focus | Healthcare & Life Sciences PEF |
| Highest 2026 tier | Tier II |
Activities and investment capabilities
ArchiMed also brings substantial European representation to the ranking. Its portfolio demonstrates that healthcare private equity extends beyond U.S. provider consolidation into medical technology, diagnostics, pharmaceutical infrastructure, and specialized healthcare manufacturing.
Healthcare investing
Equity investment across healthcare services, products and technology.
Life sciences exposure
Capital for pharmaceutical, biotechnology, medtech and outsourced-service platforms.
Sector value creation
Support informed by regulation, reimbursement, clinical workflows and market access.
Strategy and transaction coverage
Strategy and sector coverage
Healthcare services; life sciences; pharmaceuticals; medtech; diagnostics; healthcare IT
Transaction and ownership contexts
Buyouts; growth investments; recapitalizations; platform formation; add-on acquisitions
Market position
ArchiMed fits Tier II because it combines category purity, active international development, and a recognizable healthcare investment franchise. Its breadth across company sizes and subsectors gives it a strong position among established specialists.
ArchiMed is assessed within the Healthcare & Life Sciences PEF framework. For wider market context, see The Mid-Market Advantage in Healthcare Private Equity.
Competitive context
ArchiMed is recognized Tier II in Top 30 Healthcare & Life Sciences PEF 2026. The ranking compares firms by institutional relevance, specialist capability, investment activity, operating depth and market positioning. Comparable-firm links below support navigation and do not imply that every institution competes for every transaction or asset.
Leadership and governance
Leadership, investment-committee composition and operating resources may change over time. Current information should be confirmed through ArchiMed’s official website.
| Leadership area | Current source |
|---|---|
| Investment and operating leadership | Current team and governance information |
Corporate and public information
This profile refers to ArchiMed as the public-facing investment organization. Individual funds, management companies, advisers and regulated entities may use separate legal names across jurisdictions.
Corporate and disclosure information
| Organization | ArchiMed |
| Headquarters | Lyon, France |
| Public website | www.archimed.group |
| Profile basis | Public institutional information and Capital Ranking editorial research |
Ranking recognition
Related Economy analysis
Selected Economy Markets articles provide context for the investment, diligence, financing and value-creation themes relevant to this firm:
- The Mid-Market Advantage in Healthcare Private Equity
- Middle-Market Private Equity: Returns, Scale and Manager Selection
- Private Equity Technology Due Diligence in the AI Era
